- Home
- SMSI vs LYRA Comparison
SMSI vs LYRA Comparison
Compare SMSI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- LYRA
- Stock Information
- Founded
- SMSI 1982
- LYRA 2005
- Country
- SMSI United States
- LYRA United States
- Employees
- SMSI N/A
- LYRA N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- LYRA Medical/Dental Instruments
- Sector
- SMSI Technology
- LYRA Health Care
- Exchange
- SMSI Nasdaq
- LYRA Nasdaq
- Market Cap
- SMSI 14.3M
- LYRA 11.6M
- IPO Year
- SMSI 1995
- LYRA 2020
- Fundamental
- Price
- SMSI $0.73
- LYRA $7.04
- Analyst Decision
- SMSI Strong Buy
- LYRA Hold
- Analyst Count
- SMSI 1
- LYRA 1
- Target Price
- SMSI $5.00
- LYRA $16.00
- AVG Volume (30 Days)
- SMSI 145.0K
- LYRA 15.1K
- Earning Date
- SMSI 08-06-2025
- LYRA 08-12-2025
- Dividend Yield
- SMSI N/A
- LYRA N/A
- EPS Growth
- SMSI N/A
- LYRA N/A
- EPS
- SMSI N/A
- LYRA N/A
- Revenue
- SMSI $18,658,000.00
- LYRA $770,000.00
- Revenue This Year
- SMSI $0.03
- LYRA N/A
- Revenue Next Year
- SMSI $52.29
- LYRA $123.46
- P/E Ratio
- SMSI N/A
- LYRA N/A
- Revenue Growth
- SMSI N/A
- LYRA N/A
- 52 Week Low
- SMSI $0.52
- LYRA $3.81
- 52 Week High
- SMSI $1.95
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- SMSI 49.22
- LYRA 44.86
- Support Level
- SMSI $0.71
- LYRA $6.91
- Resistance Level
- SMSI $0.77
- LYRA $7.50
- Average True Range (ATR)
- SMSI 0.04
- LYRA 0.35
- MACD
- SMSI 0.01
- LYRA 0.09
- Stochastic Oscillator
- SMSI 66.58
- LYRA 30.07
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.